APTORUM GROUP LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.85 USD | -20.29% |
|
-16.30% | +57.23% |
| Apr. 30 | Aptorum Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 06 | Top Midday Gainers | MT |
Presenter SpeechCraig Brelsford (Attendees)Darren, great to see you again. Welcome. ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Aptorum Group Limited is a United Kingdom-based clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore's Agency for Science, Technology and Research.
Sector
Pharmaceuticals
Calendar
2024-09-09
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +57.23% | 21.06M | |
| +37.78% | 723B | |
| +31.73% | 598B | |
| -3.51% | 364B | |
| +19.94% | 331B | |
| +5.14% | 288B | |
| +15.77% | 244B | |
| +9.73% | 210B | |
| -4.99% | 208B | |
| +9.32% | 169B |
- Stock Market
- Equities
- APM Stock
- News Aptorum Group Limited
- Transcript : Aptorum Group Limited - Pre Recorded Special Call
